Chinese stock market Chinese medicine stocks fell on Tuesday (December 27), which continued the decline of the competition of Paxlovid, the treatment of Paxlovid in the face of Pfizer's crown disease.
The Dow Jones News Agency reported that the highest decline in Yiling Pharmaceutical in Shijiazhuang was 9.6%; the company is a traditional Chinese pharmaceutical producer that produces crown diseases. Its stock price has fallen from the peak on December 8th 40%, Then PaxLovid began to be widely used in China.
PaxLovid's dealer in China, Chinese medicine, fell by 8.9%. Previously, the company said on Monday (26th) that PaxLovid could only be purchased in the hospital.This limits the company to sell the drug more widely through e -commerce and other channels.
In mid -December, China Medicine signed an agreement to supply Paxlovid of Pfizer in China; after China has greatly relaxed the epidemic prevention policy, the crown disease epidemic in the past few weeks has spread rapidly across the country.
At 2:57 pm on Tuesday, the stock price of Ling Pharmaceutical fell 7.61%to 32.55 yuan (RMB, the same below, about S $ 6.3), and the stock price of Chinese pharmaceuticals fell 6.06%to 18.90 yuan.
